Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ackermann, G.
Right arrow Articles by Rodloff, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ackermann, G.
Right arrow Articles by Rodloff, A. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 115-119
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

In vitro activity of telithromycin (HMR 3647) and seven other antimicrobial agents against anaerobic bacteria

G. Ackermann*, R. Schaumann, B. Pless, M. C. Claros and A. C. Rodloff

Institute for Medical Microbiology and Epidemiology of Infectious Diseases, Liebigstrasse 24, University of Leipzig, D-04103 Leipzig, Germany

We assessed the in vitro activity of telithromycin (HMR 3647) and seven other antimicrobials against 292 strains of obligately anaerobic bacteria. MICs were determined with the microdilution technique and Wilkins–Chalgren broth according to DIN 58940-83. MIC50/MIC90s (mg/L) for telithromycin were 4/4 for Bacteroides fragilis, Bacteroides ovatus and Bacteroides thetaiotaomicron, 2/4 for Fusobacterium spp. and Bilophila wadsworthia, 2/2 for Bacteroides caccae, 1/4 for Bacteroides vulgatus, 0.25/4 for Prevotella spp., >=0.03/0.5 for Clostridium spp. and 0.125/4 for Peptostreptococcus spp.

* Corresponding author. Tel: +49-341-9715200; Fax: +49-341-9715209; E-mail: ackermg{at}medizin.uni-leipzig.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
B. A. Lipsky, P. Giordano, S. Choudhri, and J. Song
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate
J. Antimicrob. Chemother., August 1, 2007; 60(2): 370 - 376.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Ackermann and A. C. Rodloff
Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide
J. Antimicrob. Chemother., March 1, 2003; 51(3): 497 - 511.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.